The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours
Open Access
- 28 April 2023
- journal article
- research article
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 36, 100775
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Advancing human genetics research and drug discovery through exome sequencing of the UK BiobankNature Genetics, 2021
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2020
- Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategyNature Communications, 2020
- Implementation of a molecular tumor board at a regional level to improve access to targeted therapyInternational Journal of Clinical Oncology, 2020
- Molecular profiling for precision cancer therapiesGenome Medicine, 2020
- A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)Annals of Oncology, 2018
- Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor BoardJCO Precision Oncology, 2017
- Key Lessons Learned from Moffitt’s Molecular Tumor Board: The Clinical Genomics Action Committee ExperienceThe Oncologist, 2017
- Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical CenterThe Oncologist, 2015
- Molecular Tumor Board: The University of California San Diego Moores Cancer Center ExperienceThe Oncologist, 2014